You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君實生物(01877.HK)與美國腫瘤藥公司簽合作及許可協議
阿思達克 07-14 09:03
君實生物(01877.HK)公布,公司與Revitope簽署了研發合作及許可協議,根據協議,雙方將利用Revitope的雙抗原導向T細胞嵌合活化技術平台和公司的抗體技術平台合作研發新一代T細胞嵌合活化腫瘤免疫療法。Revitope將負責針對公司所挑選靶點設計5組不同的TEAC腫瘤免疫療法藥物。公司將獲得協議中產品在全球範圍內的獨佔許可。

Revitope是一家私營腫瘤藥公司,專注於開發以創新型腫瘤特異性抗體為基礎的生物療法,其總部位於美國馬薩諸塞州劍橋市。

雙方將在發現階段進行合作,君實生物將主導協議中TEAC分子的臨床開發和商業化,並將向Revitope支付一筆首付款。針對每組TEAC分子,Revitope將有可能另外獲得研發和商業化里程碑款,外加淨銷售額的銷售分成。君實生物承諾將按照雙方同意的條款和條件,在遵守所有適用法律的前提下以1,000萬美元對Revitope Oncology進行股權投資,獲得的股份轉換後佔Revitope Oncology總股本的9.99%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account